curcumin + docetaxel

Curcumin + docetaxel is a combination therapy consisting of curcumin, a polyphenolic compound derived from the turmeric plant (Curcuma longa), and docetaxel, a taxane-class chemotherapeutic agent. Curcumin exhibits anti-inflammatory and antineoplastic properties through modulation of multiple signaling pathways involved in cell proliferation, apoptosis, and metastasis. Docetaxel acts primarily by stabilizing microtubules, thereby inhibiting cell division and inducing apoptosis in cancer cells. Preclinical studies have shown that curcumin can enhance the cytotoxicity of docetaxel by modulating apoptotic pathways (e.g., PARP/caspase-3), downregulating pro-survival markers (e.g., PI3K/AKT/NF-kappa B), affecting cell cycle regulators (cyclins), and potentially overcoming drug resistance mechanisms such as P-glycoprotein-mediated efflux[1][5][10]. Clinical trials have evaluated this combination mainly in metastatic castration-resistant prostate cancer (mCRPC) and advanced/metastatic breast cancer; however, phase II studies did not demonstrate significant improvement in progression-free survival or overall survival compared to standard therapy with docetaxel alone[6][7][8][9].